Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022

作者：CSCO BC guideline working group, Zefei Jiang, Erwei Song, Cuizhi Geng, Yueyin Pan, Xiaojia Wang, Haibo Wang, Shuseng Wang, Xiang Wang, Jiong Wu, Yongmei Yin, Qingyuan Zhang, Jiayi Chen, Yueping Liu, Kun Wang, Tao Wang, Min Yan, Jun Zhang, Jianbin Li · 发表于：Translational Breast Cancer Research · 年份：2022 · DOI：10.21037/tbcr-22-21 · 被引用次数：73 · 研究领域：Breast Cancer Treatment Studies、Cancer Genomics and Diagnostics、Colorectal Cancer Treatments and Studies

Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology (CSCO). In recent years, the availability of medical resources has become a major concern in clinical guidelines, which is particularly important for developing countries or socioeconomically diverse countries and territories. China is the world's largest developing country, with a large territory and uneven economic and academic developments. The CSCO guidelines must take into account the differences in regional development, the availability of medicines and diagnostic methods, and the social value of cancer treatment. Therefore, for each clinical problem and intervention in the CSCO guidelines, the levels of evidence should be graded according to the currently available evidences and expert consensuses, and the grades of recommendations should be based on the availability and cost-effectiveness of the products. Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the f...